

Allopurinol**Section**

Supportive medicines

- Parenteral > General injections > IV: 500 mg (as sodium) powder for injection
- Oral > Solid: 100 mg; 300 mg

Indications

Tumour lysis syndrome

Darbepoetin alfa**Section**

Supportive medicines

Indications

Therapeutic equivalent to erythropoiesis-stimulating agents for

Drug-induced aplastic anaemia

Epoetin alfa**Section**

Supportive medicines

Indications

Therapeutic equivalent to erythropoiesis-stimulating agents for

Drug-induced aplastic anaemia

Epoetin beta**Section**

Supportive medicines

Indications

Therapeutic equivalent to erythropoiesis-stimulating agents for

Drug-induced aplastic anaemia

Erythropoiesis-stimulating agents**Section**

Supportive medicines

- Parenteral > General injections > unspecified: 2000 IU per mL in vial (single-dose); 3000 IU per mL in vial (single-dose); 4000 IU per mL in vial (single-dose); 10000 IU per mL in vial (single-dose); 40000 IU per mL in vial (single-dose); 20000 IU per mL in vial (multiple-dose); 20000 IU per 2 mL in vial (multiple-dose)

Indications

Drug-induced aplastic anaemia

Mesna

Section

Supportive medicines

- Parenteral > General injections > IV: 100 mg per mL in 4 mL ampoule; 100 mg per mL in 10 mL ampoule; 100 mg per mL in 2 mL ampoule
- Oral > Solid > tablet: 400 mg; 600 mg
- Oral > Other: 600 mg
- Oral > Solid > tablet: 400 mg
- Parenteral > General injections > IV: 100 mg per mL in 4 mL ampoule; 100 mg per mL in 10 mL ampoule
- Oral > Solid: 400 mg; 600 mg

Indications

Rhabdomyosarcoma primary site

Germ cell tumour of testis

Other specified malignant neoplasms of the ovary

Osteosarcoma of bone or articular cartilage of unspecified sites

Unspecified malignant neoplasms of unspecified sites

Ewing sarcoma of bone or articular cartilage of unspecified sites

Malignant neoplasms of kidney, except renal pelvis

Burkitt lymphoma including Burkitt leukaemia

Rasburicase

Section

Supportive medicines

- Parenteral > General injections > IV: 1.5 mg in vial powder and 1 mL solvent for solution; 7.5 mg in vial powder and 5 mL solvent for solution

Indications

Tumour lysis syndrome

Zoledronic acid

Section

Supportive medicines

- Parenteral > General injections > IV: 4 mg per 5 mL in 5 mL vial; 4 mg per 100 mL in 100 mL bottle

Indications

Malignant neoplasm metastasis in bone or bone marrow